AACR Cancer Progress Report 2015

*These authors contributed to the devlopment and review of this manuscript but are unable to endorse the request for NIH funding. On Sept. 20, 2011, the American Association for Cancer Research (AACR) released its inaugural AACR Cancer Progress Report to commemorate the

[1]  J. Haldane,et al.  The Genetics of Cancer , 1933, Nature.

[2]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.

[3]  M. Kuru.  [On precancerous conditions]. , 1952, Gan.

[4]  J. Roberts.  News of Science , 1956, Science.

[5]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[6]  Education Welfare.,et al.  Smoking and Health. Report of the Advisory Committee to the Surgeon General of the Public Health Service. , 1964 .

[7]  H. Bartsch,et al.  International Agency for Research on Cancer. , 1969, WHO chronicle.

[8]  M. Eaman.  Immune system. , 2000, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[9]  Michael J Thun,et al.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.

[10]  A. F. Stewart.  Clinical practice. Hypercalcemia associated with cancer. , 2005, The New England journal of medicine.

[11]  A. F. Stewart.  Hypercalcemia Associated with Cancer , 2005 .

[12]  E. Epstein.  Basal cell carcinomas: attack of the hedgehog , 2008, Nature Reviews Cancer.

[13]  A. Ullrich,et al.  Paul Ehrlich's magic bullet concept: 100 years of progress , 2008, Nature Reviews Cancer.

[14]  K. Straif,et al.  A review of human carcinogens--Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. , 2009, The Lancet. Oncology.

[15]  K. Straif,et al.  A review of human carcinogens--Part B: biological agents. , 2009, The Lancet. Oncology.

[16]  Office on Smoking.  How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General , 2010 .

[17]  Helen X. Chen,et al.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. , 2010, The New England journal of medicine.

[18]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[19]  Wendy Leisenring,et al.  Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. , 2010, Journal of the National Cancer Institute.

[20]  E. Gaygısız,et al.  The Organisation for Economic Co-operation and Development (OECD) , 2022 .

[21]  Brigid M Lynch,et al.  Sedentary Behavior and Cancer: A Systematic Review of the Literature and Proposed Biological Mechanisms , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[22]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[23]  Yin Cao,et al.  Body Mass Index, Prostate Cancer–Specific Mortality, and Biochemical Recurrence: a Systematic Review and Meta-analysis , 2011, Cancer Prevention Research.

[24]  Lawrence H. Kushi,et al.  Following Cancer Prevention Guidelines Reduces Risk of Cancer, Cardiovascular Disease, and All-Cause Mortality , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[25]  R Peto,et al.  Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials , 2011, The Lancet.

[26]  Eric J Feuer,et al.  Projections of the cost of cancer care in the United States: 2010-2020. , 2011, Journal of the National Cancer Institute.

[27]  J. Manyika.  Big data: The next frontier for innovation, competition, and productivity , 2011 .

[28]  A. Alwan.  Global status report on noncommunicable diseases 2010. , 2011 .

[29]  S. Wacholder,et al.  Success of HPV vaccination is now a matter of coverage. , 2012, The Lancet. Oncology.

[30]  A. Ashworth,et al.  The DNA damage response and cancer therapy , 2012, Nature.

[31]  Use of indoor tanning devices by adults--United States, 2010. , 2012, MMWR. Morbidity and mortality weekly report.

[32]  P. Moore,et al.  Merkel cell carcinoma: a virus-induced human cancer. , 2012, Annual review of pathology.

[33]  G. Colditz,et al.  Commentary: eight ways to prevent cancer: a framework for effective prevention messages for the public , 2012, Cancer Causes & Control.

[34]  A. Coveler,et al.  Chronic Myeloid Leukemia (CML) , 2012 .

[35]  C. Karema,et al.  Achieving high coverage in Rwanda's national human papillomavirus vaccination programme. , 2012, Bulletin of the World Health Organization.

[36]  Chris Fellner.  Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. , 2012, P & T : a peer-reviewed journal for formulary management.

[37]  Peter Boyle,et al.  Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis , 2012, BMJ : British Medical Journal.

[38]  P. Porter,et al.  Body mass index, tumor characteristics, and prognosis following diagnosis of early-stage breast cancer in a mammographically screened population , 2012, Cancer Causes & Control.

[39]  Sameer M. Siddiqi,et al.  Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. , 2012, Journal of the National Cancer Institute.

[40]  A. Feigl,et al.  The Global Economic Burden of Noncommunicable Diseases , 2012 .

[41]  G. Colditz,et al.  Preventability of cancer: the relative contributions of biologic and social and physical environmental determinants of cancer mortality. , 2012, Annual review of public health.

[42]  Stuart L Schreiber,et al.  AACR Cancer Progress Report 2012 , 2012, Clinical Cancer Research.

[43]  C. Garnett,et al.  U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis , 2012, Clinical Cancer Research.

[44]  M. Plummer,et al.  Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. , 2012, The Lancet. Oncology.

[45]  Aasma Shaukat,et al.  Long-term mortality after screening for colorectal cancer. , 2013, The New England journal of medicine.

[46]  G. Armstrong,et al.  Clinical ascertainment of health outcomes among adults treated for childhood cancer. , 2013, JAMA.

[47]  Janet E. Fulton,et al.  Adult Participation in Aerobic and Muscle-Strengthening Physical Activities — United States, 2011 , 2013, MMWR. Morbidity and mortality weekly report.

[48]  Jacques Ferlay,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet] , 2013 .

[49]  Helen Thompson,et al.  US National Cancer Institute's new Ras project targets an old foe , 2013, Nature Medicine.

[50]  Raffaella Casadei,et al.  An estimation of the number of cells in the human body , 2013, Annals of human biology.

[51]  R. Herbst,et al.  Assessing Tobacco Use by Cancer Patients and Facilitating Cessation: An American Association for Cancer Research Policy Statement , 2013, Clinical Cancer Research.

[52]  M. Dewhirst,et al.  Effects and potential mechanisms of exercise training on cancer progression: A translational perspective , 2013, Brain, Behavior, and Immunity.

[53]  Robert N. Anderson,et al.  Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)–Associated Cancers and HPV Vaccination Coverage Levels , 2013, Journal of the National Cancer Institute.

[54]  Jiaquan Xu,et al.  Deaths: final data for 2010. , 2013, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[55]  Philadelphia County,et al.  Human Papillomavirus Vaccination Coverage Among Adolescent Girls, 2007-2012, and Postlicensure Vaccine Safety Monitoring, 2006-2013 — United States , 2013 .

[56]  Elaine R Mardis,et al.  AACR Cancer Progress Report 2013 , 2013, Clinical Cancer Research.

[57]  Kurt Straif,et al.  The carcinogenicity of outdoor air pollution. , 2013, The Lancet Oncology.

[58]  T. Holford,et al.  Tobacco Control and the Reduction in Smoking-Related Premature Deaths in the United States, 1964-2012 , 2014 .

[59]  L. J. van 't Veer,et al.  Reliable and Effective Diagnostics Are Keys to Accelerating Personalized Cancer Medicine and Transforming Cancer Care: A Policy Statement from the American Association for Cancer Research , 2014, Clinical Cancer Research.

[60]  J. Wolchok,et al.  Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  Jack Cuzick,et al.  Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[62]  E. Mardis,et al.  AACR Cancer Progress Report 2014 , 2014, Clinical Cancer Research.

[63]  Pamela M Ling,et al.  "Smoking revolution": a content analysis of electronic cigarette retail websites. , 2014, American journal of preventive medicine.

[64]  Kassandra I. Alcaraz,et al.  Prevalence and Correlates of Smoking and Cessation-Related Behavior among Survivors of Ten Cancers: Findings from a Nationwide Survey Nine Years after Diagnosis , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[65]  G. Batist,et al.  Use of statins and the risk of death in patients with prostate cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  Antoni Ribas,et al.  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial , 2014, The Lancet.

[67]  David C. Smith,et al.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  R. Gershoni-baruch,et al.  Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers , 2014, British Journal of Cancer.

[69]  T. Holford,et al.  Tobacco control and the reduction in smoking-related premature deaths in the United States, 1964-2012. , 2014, JAMA.

[70]  A. Reuss,et al.  Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  G. Guy,et al.  Surgeon General’s Call to Action to Prevent Skin Cancer , 2014, Morbidity and Mortality Weekly Report.

[72]  T. Pechacek,et al.  CDC Grand Rounds: Global Tobacco Control , 2014, MMWR. Morbidity and mortality weekly report.

[73]  Jenny Jeyarajah,et al.  Human Papillomavirus Vaccination Coverage Among Adolescents, 2007–2013, and Postlicensure Vaccine Safety Monitoring, 2006–2014 — United States , 2014, MMWR. Morbidity and mortality weekly report.

[74]  Qing He,et al.  Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.

[75]  D. Esposito,et al.  Dragging ras back in the ring. , 2014, Cancer cell.

[76]  K. Flegal,et al.  Prevalence of Childhood and Adult Obesity in the United States, 2011–2012 , 2014 .

[77]  C. Castoro,et al.  Obesity is a risk factor for multifocal disease and recurrence after colorectal cancer surgery: a case-control study. , 2014, Anticancer research.

[78]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[79]  K. Schmitz,et al.  Influence of weight training on skeletal health of breast cancer survivors with or at risk for breast cancer-related lymphedema , 2014, Journal of Cancer Survivorship.

[80]  M. Beksac,et al.  Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. , 2014, The Lancet. Oncology.

[81]  J. Wolchok,et al.  Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.

[82]  A. Hartman,et al.  The association between demographic and behavioral characteristics and sunburn among U.S. adults - National Health Interview Survey, 2010. , 2014, Preventive medicine.

[83]  M. Chren,et al.  International prevalence of indoor tanning: a systematic review and meta-analysis. , 2014, JAMA dermatology.

[84]  Brian A. King,et al.  Current Cigarette Smoking Among Adults — United States, 2005–2012 , 2014, MMWR. Morbidity and mortality weekly report.

[85]  G. Colditz.  Carpe Diem: time to seize the opportunity for cancer prevention. , 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[86]  D. Ransohoff,et al.  Multitarget stool DNA testing for colorectal-cancer screening. , 2014, The New England journal of medicine.

[87]  T. Rebbeck.  Precision Prevention of Cancer , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[88]  G. Tonini,et al.  Denosumab for treatment of hypercalcemia of malignancy. , 2014, The Journal of clinical endocrinology and metabolism.

[89]  B. Lushniak,et al.  The Health consequences of smoking—50 years of progress : a report of the Surgeon General , 2014 .

[90]  Andreas Sashegyi,et al.  Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial , 2014, The Lancet.

[91]  D. Porter,et al.  Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas. , 2015 .

[92]  K. Schmitz,et al.  Weight Lifting and Physical Function Among Survivors of Breast Cancer: A Post Hoc Analysis of a Randomized Controlled Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  J. Lunceford,et al.  Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012. , 2015 .

[94]  C. Matthews,et al.  Pre- and postdiagnosis physical activity, television viewing, and mortality among patients with colorectal cancer in the National Institutes of Health-AARP Diet and Health Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  Laurie Burke,et al.  Patient-Focused Drug Development: A New Direction for Collaboration , 2015, Medical care.

[96]  R. Dummer,et al.  Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. , 2015, The Lancet. Oncology.

[97]  S. Kaye,et al.  Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different? , 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[98]  Jennifer A. Hobin,et al.  Electronic Nicotine Delivery Systems: A Policy Statement from the American Association for Cancer Research and the American Society of Clinical Oncology , 2015, Clinical Cancer Research.

[99]  Leilei Xia,et al.  Impact of body mass on recurrence and progression in Chinese patients with Ta, T1 urothelial bladder cancer , 2015, International Urology and Nephrology.

[100]  J. Lunceford,et al.  Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012. , 2015 .

[101]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[102]  Sung-Bae Kim,et al.  Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. , 2015, The New England journal of medicine.

[103]  R. Larson,et al.  Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. , 2015, The Lancet. Oncology.

[104]  Wei Shi,et al.  Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[106]  Craig M. Hales,et al.  Vaccination Coverage Among Adults, Excluding Influenza Vaccination — United States, 2013 , 2015, MMWR. Morbidity and mortality weekly report.

[107]  Nikki A. Hawkins,et al.  Patterns of sunscreen use on the face and other exposed skin among US adults. , 2015, Journal of the American Academy of Dermatology.

[108]  D. Schadendorf,et al.  Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  Oecd Indicators.  Health at a Glance 2015 , 2015 .

[110]  W. Willett,et al.  Early Life Body Fatness and Risk of Colorectal Cancer in U.S. Women and Men—Results from Two Large Cohort Studies , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[111]  E. Giovannucci,et al.  Adolescent body mass index and erythrocyte sedimentation rate in relation to colorectal cancer risk , 2015, Gut.

[112]  Gretchen A. Stevens,et al.  Global burden of cancer attributable to high body-mass index in 2012: a population-based study. , 2015, The Lancet. Oncology.

[113]  G. Linette,et al.  Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.

[114]  Jerry Avorn,et al.  The $2.6 billion pill--methodologic and policy considerations. , 2015, The New England journal of medicine.

[115]  Ayala Hubert,et al.  Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  Keunchil Park,et al.  Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). , 2015 .

[117]  Kevin A. Henry,et al.  Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State , 2015, Journal of the National Cancer Institute.

[118]  Brian A. King,et al.  Tobacco Use Among Middle and High School Students — United States, 2011–2014 , 2015, MMWR. Morbidity and mortality weekly report.

[119]  A. Ziogas,et al.  Sociodemographic Disparities in Advanced Ovarian Cancer Survival and Adherence to Treatment Guidelines , 2015, Obstetrics and gynecology.

[120]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[121]  J. Bellon.  Personalized Radiation Oncology for Breast Cancer: The New Frontier. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  Wanrudee Isaranuwatchai,et al.  A cost‐effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer , 2015, Cancer.

[123]  David Wholley,et al.  Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400 , 2015, Clinical Cancer Research.

[124]  Greta M. Massetti,et al.  Vital Signs: Melanoma Incidence and Mortality Trends and Projections — United States, 1982–2030 , 2015, MMWR. Morbidity and mortality weekly report.

[125]  Xin Huang,et al.  The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. , 2015, The Lancet. Oncology.

[126]  E. Jaffee,et al.  Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[127]  B. Levine,et al.  Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR)-modified autologous T cells (CTL019) in advanced multiple myeloma. , 2015 .

[128]  B. Vogelstein,et al.  PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[129]  J. Cuzick,et al.  A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. , 2015, The New England journal of medicine.

[130]  G. Linette,et al.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.

[131]  E. Van Cutsem,et al.  Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. , 2015, The Lancet. Oncology.

[132]  R. Berger,et al.  Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[133]  R. Advani,et al.  Ibrutinib in previously treated Waldenström's macroglobulinemia. , 2015, The New England journal of medicine.

[134]  Frances E. Thompson,et al.  Adults Meeting Fruit and Vegetable Intake Recommendations — United States, 2013 , 2015, MMWR. Morbidity and mortality weekly report.

[135]  B. Monk,et al.  Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). , 2015, The Lancet. Oncology.

[136]  P. Hegde,et al.  A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC). , 2015 .

[137]  B. Vogelstein,et al.  Variation in cancer risk among tissues can be explained by the number of stem cell divisions , 2015, Science.

[138]  Jennifer A. Hobin,et al.  Electronic Nicotine Delivery Systems: A Policy Statement from the American Association for Cancer Research and the American Society of Clinical Oncology , 2015, Clinical Cancer Research.

[139]  A. Jemal,et al.  Where Can Colorectal Cancer Screening Interventions Have the Most Impact? , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[140]  Graham A. Colditz,et al.  Prevalence of Overweight and Obesity in the United States, 2007-2012. , 2015, JAMA internal medicine.

[141]  R. Motzer,et al.  Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[142]  K. Yabroff,et al.  How Are Spousal Depressed Mood, Distress, and Quality of Life Associated with Risk of Depressed Mood in Cancer Survivors? Longitudinal Findings from a National Sample , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[143]  E. Mardis,et al.  A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells , 2015, Science.

[144]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[145]  J. Kench,et al.  Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.

[146]  Massimo Cristofanilli,et al.  Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. , 2015, The New England journal of medicine.

[147]  Gloria S. Huang,et al.  The impact of obesity on prostate cancer recurrence observed after exclusion of diabetics , 2015, Cancer Causes & Control.

[148]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[149]  S. Gettinger,et al.  Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[150]  Geoffrey C Kabat,et al.  Adherence to cancer prevention guidelines and cancer incidence, cancer mortality, and total mortality: a prospective cohort study. , 2015, The American journal of clinical nutrition.

[151]  Connie Lim,et al.  Youth Risk Behavior Surveillance - United States, 2015. , 2016, Morbidity and mortality weekly report. Surveillance summaries.